Computational analysis links blood RNA patterns to ALS diagnosis and prognosis

Updated on: May 17,2025 0

Computational analysis links blood RNA patterns to ALS diagnosis and prognosis

Updated on:May 17,2025 0

Combination therapy tackles drug resistance in lung cancer with common KRAS mutation

Updated on: April 22,2025 0

Combination therapy tackles drug resistance in lung cancer with common KRAS mutation

Updated on:April 22,2025 0

Novel radiotracer identifies biomarker for triple-negative breast cancer

Updated on: April 21,2025 0

Novel radiotracer identifies biomarker for triple-negative breast cancer

Updated on:April 21,2025 0

Artificial intelligence predicts kidney cancer therapy response

Updated on: May 18,2025 0

Artificial intelligence predicts kidney cancer therapy response

Updated on:May 18,2025 0

Who updates list of essential medicines to include GLP-1s

Updated on: September 29,2025 0

Who updates list of essential medicines to include GLP-1s

Updated on:September 29,2025 0

Newly discovered cells in connective tissue open up strategy against pancreatic cancer

Updated on: May 17,2025 0

Newly discovered cells in connective tissue open up strategy against pancreatic cancer

Updated on:May 17,2025 0

RNA molecule identified as possible driver of gastric cancer

Updated on: April 21,2025 0

RNA molecule identified as possible driver of gastric cancer

Updated on:April 21,2025 0

Weekly Update of Drug News-22/10/2025

On Oct 6 2025, AbbVie announced positive topline results from its Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) for upper limb essential tremor compared to placebo.

Updated on: October 22,2025 0

Weekly Update of Drug News-22/10/2025

On Oct 6 2025, AbbVie announced positive topline results from its Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) for upper limb essential tremor compared to placebo.

Updated on:October 22,2025 0

Medicine Net Update 2025/07/10

On Jul 03, 2025, Norvatis announced results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Updated on: July 16,2025 0

Medicine Net Update 2025/07/10

On Jul 03, 2025, Norvatis announced results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Updated on:July 16,2025 0

Large-scale analysis of attitudes toward drugs reveals growing acceptance of psychedelics

Updated on: July 09,2025 0

Large-scale analysis of attitudes toward drugs reveals growing acceptance of psychedelics

Updated on:July 09,2025 0